Despite new antifungal treatment strategies, invasive aspergillosis (IA) remains a principal cause of infectious mortality after bone marrow transplantation (BMT). We reviewed the medical records of 93 allogeneic and 149 autologous transplant recipients during a 20 month period, with attention to cases of proven or probable IA. No autologous transplant recipient developed IA, whereas IA was seen in 15.1% of allogeneic recipients (including two of five patients with a prior history of IA despite prophylaxis), for an overall incidence of 5.8%. The median time to occurrence was 92 days post transplant, with no de novo cases developing prior to engraftment. Survival 100 days from diagnosis was 29%. Risk factors for the development of IA included у21 days of corticosteroid therapy of у1 mg/kg/day and post-transplant cytomegalovirus (CMV) infection. These two risk factors were statistically linked. Our data illustrate a shift toward a later occurrence of posttransplant IA, suggesting a need for close, prolonged surveillance in the outpatient environment. The contributory role of protracted corticosteroid use is also highlighted. These data have important implications in an era of alternate donor transplants and more intense immunosuppression. Established strategies implementing newer, less toxic antifungal agents as prophylaxis in high-risk patients are needed.
sources and more profound immunosuppression, including T cell depletion techniques, which weaken host defenses in the post-engraftment period. The time of onset in autologous transplant recipients is typically during the preengraftment period, whereas later infections are often also seen in allogeneic recipients. 6 Specific knowledge of the usual time of onset and identifiable risk factors for IA is essential to the development of more effective prevention strategies and the application of new therapeutic techniques. Previously identified risk factors include age, 3, 7 unrelated donor, 3, 4 transplant outside of a laminar air flow room, 5 low cell dose, 7 recipient CMV seropositivity, 7 persistent or prolonged neutropenia, 5, 8 early corticosteroid use for acute graft-versus-host disease (GVHD) prophylaxis, 9 high-grade acute GVHD, 1,3,4 chronic GVHD 4, 8 and graft rejection. 10 Decreased risk for IA has been ascribed to housing patients in a high-efficiency particulate air (HEPA) filtered environment. 11 To our knowledge, no data exist comparing the risk for IA using different sources of harvested stem cells (peripheral blood vs bone marrow). Furthermore, the need exists for more data regarding the role of GVHD, as well as duration and dose of corticosteroids as predisposing factors for infection.
In this study, we reviewed the current epidemiology of IA in the Bone Marrow Transplant Unit at the University of Florida with specific attention to the time of onset and survival. These findings were compared to those reported in a similar epidemiologic study done at this institution between 1981 and 1985.
11 Such a comparison can illustrate the effects of new transplantation techniques and serve as a barometer of the effectiveness of antifungal strategies employed in the interim. Another purpose of our study was to identify specific risk factors which could be incorporated into the design of future prevention and treatment strategies. We also sought to determine the degree to which prolonged steroid usage was associated with a higher incidence of IA.
Methods

Patient population
We reviewed the medical records of all patients who underwent peripheral blood or bone marrow transplantation at the University of Florida between 22 April 1997 and 31 December 1998. Our cohort consisted of 93 consecutive allogeneic and 149 consecutive autologous transplant recipients. Median follow-up of patients surviving until analysis was 428 days for allogeneic recipients and 328 days for autologous recipients. Pretransplant patient characteristics are presented in Table 1 .
Study methods
Information was extracted from medical records pertaining to the occurrence, site of involvement, time of onset, and fungal species (when available) for invasive Aspergillus infections. The following variables were analyzed as possible risk factors for the development of IA: age, sex, disease type, disease status at transplant, donor type, stem cell source, Aspergillus infection prior to BMT, duration of neutropenia, use of empiric amphotericin during neutropenia, CMV infection, GVHD prophylaxis, occurrence of acute and/or chronic GVHD, and duration of steroid use post transplant. Information on the treatment of recognized cases of IA and survival after diagnosis was also recorded.
Disease status
To analyze the effect of disease status at the time of transplant on developing IA, we divided our patients into four 
Transplant care
The conditioning regimen consisted of chemotherapy ± total body irradiation (TBI). Allogeneic transplant recipients received one of the following GVHD prophylaxis regimens: cyclosporine A + methotrexate (n = 54), tacrolimus + methotrexate (n = 22), other (n = 17). All patients were housed in laminar air flow rooms throughout the period of neutropenia. T cell depletion was used only in mismatched patients (n = 6). Antimicrobial prophylaxis consisting of acyclovir and fluconazole was used. When prior Aspergillus infection had been documented, prophylactic therapy with amphotericin B (n = 2), itraconazole (n = 1), or both in sequence (n = 2) was used to prevent reactivation. During neutropenia, broad-spectrum antibiotics were administered for fever higher than 38.5°C. In most cases cefepime was initiated, followed by the addition of vancomycin or an aminoglycoside if fever persisted. In the event of fevers lasting 72-96 h without an identified source, amphotericin B or a lipid amphotericin B formulation was added empirically and continued until neutrophil recovery.
GVHD and steroid use
The occurrence of acute and chronic GVHD was established in accordance with published diagnostic criteria. 12 Specific data were collected regarding the dose and duration of steroid therapy. Grade 2 or higher acute GVHD was treated wth methylprednisolone at an initial dose of 2 mg/kg/day followed by a tapering schedule. 13 The taper generally occurred at 4 day intervals so that doses of у1.0 mg/kg/day were given for р16 days unless GVHD was uncontrolled. At the time of analysis, patients were divided into two groups according to whether or not they had received at least 21 days of у1 mg/kg/day of corticosteroid therapy.
Definition of invasive Aspergillosis
Cases of invasive aspergillosis were classified as either proven or probable.
14 Patients were considered to have proven IA when either (1) Aspergillus was identified by culture and/or microscopy of tissue taken from a normally sterile site, including autopsy findings, or (2) microscopic findings of filamentous fungus with septate hyphae and acute angle branching in the absence of a positive culture plus radiographic findings compatible with invasive fungal infection. Probable IA was defined as radiographic findings compatible with invasive fungal infection on computed tomography (CT) scan or magnetic resonance imaging (MRI) with negative culture and microscopy of the affected tissue and no other infectious pathogens identified. All cases of probable IA in this study occurred in the lungs and were supported by bronchoalveolar lavage and/or CT-directed biopsy of involved areas that failed to provide another etiology for disease. Confirmatory autopsies were often declined by family members. The date when laboratory or radiographic evidence of disease was first noted was designated the date of diagnosis of IA.
Statistical methods
Univariate comparisons between patients with and without IA were performed using chi-square analysis or Fisher's exact test for categorical variables and t-test for continuous variables. P values р0.05 were considered statistically significant. Analyses were performed using SAS or Statistica. Simple multivariate analyses were performed using the GENMOD procedure.
Results
Frequency of IA
Of 149 autologous transplant recipients, none (0%) developed proven or probable IA (Table 2) . Of 93 allo- niger. The remaining case was not fully speciated but was determined to be a non-fumigatus type. Four of five cases of probable IA were pulmonary infections, and the fifth case was disseminated IA (Table 3 ). All five patients had either bronchoalveolar lavage or CT-guided lung biopsy to exclude other infectious etiologies.
Time of occurrence
The median time to development of IA after transplant was 92 days (range 31-459) ( Table 4) . No de novo cases occurred prior to engraftment. Only one reactivation case occurred before engraftment. Survival of patients from the time of diagnosis of IA was 64% at 30 days and 29% at 100 days. The principal cause of death was deemed to be IA in nine of 10 patients not surviving 100 days. All four patients surviving 100 days past diagnosis were still alive at the time of the study (180-566 days in follow-up). Of these four patients, two were classified as having probable IA and two had proven IA.
Risk factors for development of IA
Risk factors in allogeneic BMT patients were assessed (Table 5 ). Risk for IA was not significantly affected by sex of the recipient, stem cell source, duration of neutropenia, disease status, or disease type. Among allogeneic transplant recipients, the donor type was not associated with IA. Interestingly, however, three of six recipients of T cell-depleted grafts developed IA. No significant difference was seen among various GVHD prophylaxis regimens with regard to risk for IA. The presence of acute and/or chronic GVHD was not significantly correlated with risk of developing IA in our study (P = 0.156) ( Table 5 ). However, patients who received у21 days of у1 mg/kg/day of steroid therapy had a significantly greater risk of developing IA (21% vs 5%) (P = 0.034) compared to those requiring less steroids.
Patients who developed post-transplant CMV infection (viremia or localized infection) were more likely to develop IA. Ten of 14 (71%) patients with IA had documented CMV infection, while only 28 of 79 (35%) patients without IA had evidence of CMV infection (P = 0.012). Using multivariate analysis, however, CMV infection was statistically associated with cumulative steroid dose and not an independent risk factor.
Discussion
The current study documents an overall incidence of IA of 5.8% among all transplant recipients during the study period. Recent studies have reported infection rates of 3.6% to 15%. 4, 5, 6, 10 The aforementioned study performed at our institution reported the overall incidence of IA to be 12.3%. 11 However, all cases occurred in patients housed in rooms without a high-efficiency particulate air (HEPA) filtered environment, a setting now broadly accepted as effective at decreasing nosocomial Aspergillus infections, making comparison difficult. The stable rate of infection seen over time in the face of more frequent high risk transplants and more profound immunosuppression may actually represent marginal progress.
There were no documented cases of IA among autologous transplant recipients. In the past, this population represented a significant proportion of cases of IA occurring early post transplant. 6 This improvement may be due to more rapid engraftment afforded by the use of hematopoietic growth factors and grafts with higher stem cell content and the routine use of HEPA filtered hospital rooms.
The median time of onset after transplant of IA was 92 days, later than the median of 50 days reported earlier from this institution. 11 Recent studies have shown the median time of onset of infection to be as late as 136 days in allogeneic recipients. 4 A later occurrence of IA suggests that acquisition of infection is now occurring in the community after hospital discharge. This trend merits consideration as attempts are made to shift transplantation to the outpatient setting where air filters are not present. The use of corticosteroids in the post-transplant period for prevention and treatment of GVHD has been associated with a higher risk of developing IA. Ribaud et al 1 described an association between cumulative steroid dose and survival rate among transplant recipients with IA. Data are scanty, however, regarding specific doses and duration of therapy and their effect on infection risk. In our study, patients who received у1 mg/kg/day of methylprednisolone or prednisone for у21 days had a significantly higher risk of developing IA. Further characterization of this relationship may have implications in deciding which patients should receive antifungal prophylaxis, especially as newer, less toxic options become available.
CMV infection (pneumonitis or viremia) has been shown to be a risk factor for IA in lung and BM transplant recipients. 15 Recipient CMV seropositivity is a significant risk factor in bone marrow transplant patients. 7 However, posttransplant CMV infection has not been clearly shown to increase risk for IA. Among allogeneic transplant recipients in our study, 26.3% of patients with documented CMV infection developed IA compared to only 7.2% of those without CMV infection. This difference was statistically linked to cumulative steroid dose as a risk factor.
In conclusion, despite the advent of new therapeutic options for IA, successful outcomes for patients with established infection are infrequent. Improved diagnostic assays allowing earlier detection are being developed which may influence success rates. At present, however, effective prevention strategies are needed. Defining the population at risk will allow judicious use of newer prophylactic antifungal therapy. These and other data can be applied toward this goal.
